Connect with us

Hi, what are you looking for?

Top Stories

Editor's Pick

Moderna booster candidate shows strong response against Omicron subvariants

MODERNA, INC. said on Wednesday that an updated version of its COVID-19 vaccine designed to target the Omicron variant also generated a strong immune response against the fast-spreading Omicron subvariants BA.4 and BA.5, which have gained a foothold in the US in recent weeks.

The updated vaccine, which Moderna is hoping will be approved for use as a booster shot for the fall, is a bivalent vaccine, meaning it contains vaccine designed to target two different coronavirus variants — the original variant from 2020 and the Omicron variant that was circulating widely last winter.

Moderna said that while the shot elicited a weaker response versus BA.4 and BA.5 than it does against the BA.1 subvariant it was specifically designed to combat, the data suggests the new shot could produce “lasting protection against the whole family of Omicron variants.”

“This is a strong, powerful antibody response,” Moderna Chief Medical Officer Paul Burton said at a news conference. “It is probably long lasting and I think the conclusions are that boosting or primary vaccination with (the updated vaccine) really could be a turning point in our fight against SARS-cov-2 virus.”

Moderna has been producing the updated vaccine on its own dime ahead of any regulatory approvals, and Chief Executive Stephane Bancel said the company could begin supplying the shot in August.

The company plans to submit applications to regulators in the coming weeks to ask for approval of the shot — which it calls mRNA-1273.214 — for the fall season.

The two sublineages, which were added to the World Health Organization’s monitoring list in March and designated as variants of concern by the European Centre for Disease Prevention and Control, accounted for more than a third of US cases last week.

The US Food and Drug Administration plans to hold a meeting of outside experts next week to discuss the best composition of booster shots for the fall.

Pfizer and BioNTech are also testing several possible variant-adapted COVID-19 vaccines, including a bivalent candidate similar to Moderna’s.

The European Medicines Agency last week launched a rolling review of their candidates, although the companies have yet to release any data on how well they work. BioNTech this month said market clearance could come as early as August but could also take until September or later in the fall. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Editor's Pick

The Board of Investments (BoI) has cleared Sinoma Energy Conservation (Cebu) Waste Heat Recovery Co. Inc. to serve as the operator of a 4.5-megawatt...

Forex

At a time when the world is battling to get through the dreaded coronavirus pandemic, protective face masks have come out to be the...

Editor's Pick

BEWARE the “lessons of history” as drawn by charlatans, ignoramuses, or tyrants, for they will be daft, wrong, and possibly disastrous. The self-serving amateur...

Editor's Pick

The world’s food-import bill is set to jump even more than expected to a record this year, increasing the threat of hunger, especially in...

Disclaimer: SecretsOfRichDads.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 Secrets Of Richdads. All Rights Reserved.